Joshua Brody

New York University — United States

Medicine · Health Sciences

44h-index9.7kcitations340works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(147), Lymphoma Diagnosis and Treatment(112), Immunotherapy and Immune Responses(94), Cancer Immunotherapy and Biomarkers(87), Monoclonal and Polyclonal Antibodies Research(66)

Publications337 total

Abstract A011: IL-12 armored anti-macrophage CAR T cells reset and reprogram the tumor microenvironment to control metastatic ovarian and lung tumor growth
Cancer Immunology Research·2026
Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth
Cancer Cell·2026· 2 cited
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma
Future Oncology·2025Open Access
Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response
2025Open Access
Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial
Blood·2025· 1 citedOpen Access
Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population
Blood·2025Open Access
Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trial
Blood·2025Open Access
Genomic alterations in TET2 and EZH2 serve as critical drivers of clonal malignant evolution in anti-BCMA CAR-T therapy for multiple myeloma.
Blood·2025Open Access
Long-term follow up of nivolumab/ipilimumab-primed immunotransplant in patients with Relapsed/Refractory DLBCL
Blood·2025Open Access
Transcriptome sequencing of Hodgkin lymphoma Hodgkin and reed-stenberg cells reveals escape from NK cell recognition and an unfolded protein response
Blood·2025Open Access
Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7
Blood·2025
Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study
Blood·2025
Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.
Blood·2025Open Access
Fixed-duration epcoritamab in combination with bendamustine + Rituximab (BR) for first-line (1L) treatment of follicular lymphoma (FL): 3-year results from EPCORE NHL-2 arm 3 demonstrate deep and durable responses with manageable safety
Blood·2025Open Access
210 Mechanisms and impact of bystander killing by CAR T cells
Regular and Young Investigator Award Abstracts·2025Open Access
ScSeq of human antigen-escaping tumor variants reveals their plasma-cell-like phenotype 3687
The Journal of Immunology·2025Open Access
Potentiating CAR-T bystander killing by enhanced Fas/FasL signaling mitigates antigen escape in heterogeneous tumors
2025Open Access
TET2 and EZH2 Genetic Alterations Promote Malignant CAR-T Transformation in Anti-BCMA CAR-T Therapy
Clinical Lymphoma Myeloma & Leukemia·2025
Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy
New England Journal of Medicine·2025· 4 citedOpen Access
Data from Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas
2025Open Access
page 1 of 17Next →

Frequent Co-authors

Ronald Levy(13), Aurélien Marabelle(12), Holbrook E. Kohrt(10), Miriam Mérad(8), Debra K. Czerwinski(7), Brian D. Brown(6), John D. Powderly(6), Nina Bhardwaj(5), Judit Svensson‐Arvelund(5), Linda Hammerich(5), Jason J. Luke(5), Ginna G. Laport(5), Samir Parekh(5), Adeeb Rahman(4), Ranjan Upadhyay(4), Michael Yellin(4), Michael R. Green(4), Lawrence Fong(4), Brett Hughes(4), Shivaani Kummar(4)